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Abstract: Countries in Africa and the Middle East bear a heavy burden from cardiovascular 
disease. The prevalence of coronary heart disease is promoted in turn by a high prevalence of 
cardiovascular risk factors, particularly smoking, hypertension, dyslipidemia, diabetes, and 
sedentary lifestyles. Patients in Africa and the Middle East present with myocardial infarction 
at a younger age, on average, compared with patients elsewhere. The projected future burden 
of mortality from coronary heart disease in Africa and the Middle East is set to outstrip that 
observed in other geographical regions. Recent detailed nationally representative epidemiological 
data are lacking for many countries, and high proportions of transient expatriate workers in 
countries such as Saudi Arabia and the United Arab Emirates complicate the construction of 
such datasets. However, the development of national registries in some countries is beginning 
to reveal the nature of coronary heart disease. Improving lifestyles (reducing calorie intake 
and increasing physical activity) in patients in the region will be essential, although cultural 
and environmental barriers will render this difficult. Appropriate prescribing of pharmacologic 
treatments is essential in the prevention and management of cardiovascular disease. In particular, 
recent controversies relating to the therapeutic profile of beta-blockers may have reduced their 
use. The current evidence base suggests that beta-blockers are as effective as other therapies in 
preventing cardiovascular disease and that concerns relating to their use in hypertension and 
cardiovascular disease have been overstated.
Keywords: coronary heart disease, beta-blockers, cardiovascular risk factors, cardiovascular 
disease, heart failure
Introduction
Cardiovascular disease is the principal threat to health in countries in Africa and the 
Middle East, as elsewhere,1 with increases in the projected burden of mortality set to 
outstrip that observed in other geographical regions.2 These data, discussed in more 
detail in the following pages, suggest that the management of ischemic heart disease is 
suboptimal in some Middle Eastern countries, and that more aggressive management of 
cardiovascular health could bring substantial improvements to long-term clinical out-
comes. Access to health care, prompt and accurate diagnosis, and selection of appropriate 
therapy are all key determinants of outcome in patients with coronary disease.
The purpose of this review is to summarize the current status of the epidemiol-
ogy and management of coronary heart disease in countries in the region, and to 
describe initiatives being designed to address the burden of cardiovascular disease in 
the future. The review will focus on the role of beta-blockers in particular. Treatment 
with a beta-blocker is strongly recommended in guidelines for the management of 
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patients with coronary heart disease in a number of settings,3 
although a recent focus in guidelines on their potential for 
adverse metabolic effects may have restricted their use to 
some extent.4,5
Epidemiology of cardiovascular 
disease in the region
Middle East as a whole
Figure 1 shows age-standardized mortality rates compiled by 
the World Health Organization (WHO) for some countries 
in the region.1 There was a marked excess of cardiovascular 
deaths in most countries from the region compared with 
data from comparator western countries (UK, Germany 
and the US), particularly from ischemic heart disease and 
hypertensive heart disease. Moreover, the INTERHEART 
study (an international case-control analysis of the risk   factors 
for a first myocardial infarction conducted in more than 15,000 
patients presenting with myocardial infarction in 52 countries) 
showed that the median age at presentation with myocardial 
infarction was 51 years in the Middle East; this was lower 
than the median age at presentation in nine other regions, 
and was 12 years lower than the median age at presentation 
in Western Europe.6 A projected increase in coronary deaths 
in the Middle East of 171% between 1990 and 2020 was 
larger than corresponding values for “established market 
economies” (46%), India (127%), China (108%), sub-Saharan 
Africa (144%), and Latin America (144%).2
Current data regarding the prevalence of coronary heart 
disease, and its principal risk factors, are summarized below 
for a number of countries in the region. Tobacco consumption 
(including shisha, smoked in a hookah, or water-pipe),7 
  however, has emerged as a particularly important risk 
factor in the region and is considered here. Smoking rates 
have increased in most countries in North Africa and the 
Middle East, compared with decreasing rates in most 
western countries, from the latter part of the 1990s onwards 
(Figure 2).8 Consumption of khat (qat) is also a risk factor 
for coronary heart disease, particularly in Yemen and the 
Horn of Africa.9
Available data for individual countries  
in the region
Egypt
The Egyptian National Hypertension Project has provided 
the two principal sources of information on the epidemiol-
ogy of coronary heart disease in the region,10–12 in addition 
to data from the WHO (see Figure 1). This nationally repre-
sentative survey of 6733 subjects (about half of whom were 
women) found an adjusted overall prevalence of coronary 
heart disease of 8.3%. The prevalence of coronary heart 
disease was somewhat higher in women (8.9%) relative to 
men (8.0%), but was more clearly associated with an urban 
versus rural location (8.8% versus 7.2%), and age .50 years 
versus ,50 years (11.1% versus 5.1%). A high prevalence 
of hypertension in Egypt (26%) was an important driver of 
adverse cardiovascular outcomes (Table 1).10–12
Lebanon
Age, dysglycemia, hypertension, family history of coronary 
heart disease, and dyslipidemia predict the development of 
coronary heart disease in Lebanon as elsewhere.13 Nationally 
representative data on the epidemiology of coronary heart 
disease in Lebanon are lacking. However, detailed data on 
patients presenting with coronary heart disease in Lebanon 
are available from the Lebanese Interventional Coronary 
Registry. Coronary angiography remains the principal 
method for diagnosis of coronary disease and is widely 
used in Lebanon (only Germany and the US have a higher 
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Figure 1 Death rates from cardiovascular disease in selected countries in Africa and 
the Middle East. Drawn from data presented by the World Health Organization.1
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Figure 2 Trends in total cigarette consumption in the  World Health Organization Eastern 
Mediterranean and  Americas regions. Drawn from data presented by Guindon et al.8
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density of angiography facilities per head of population).14 
Cardiovascular risk factors were common in patients 
  presenting for angiography, including hypertension (60%), 
smoking (50%), diabetes (29%), hypercholesterolemia 
(29%), and family history of myocardial infarction (26%).15 
Prior cardiovascular disease was also common, including 
angina (61%) and prior myocardial infarction (13%); unstable 
angina (35%), stable angina (21.2%) and atypical chest pain 
were the most common symptoms on presentation.15
Interestingly, the ischemic burden remaining following 
myocardial infarction in patients referred for cardiac imaging 
(size of the ischemic defect and subsequent risk of mortality) 
was twice as high in a major referral center in Texas compared 
with a center in Beirut, Lebanon.16 This difference occurred 
despite a similar prevalence of cardiovascular risk factors 
between the centers, suggesting that other factors must have been 
involved in determining clinical cardiovascular outcomes.
Saudi Arabia
The Gulf Cooperative Council consists of Bahrain, Kuwait, 
Oman, Qatar, Saudi Arabia, and the United Arab Emirates. 
The Coronary Artery Disease in Saudi Arabia Study found 
a high prevalence of hypertension (26%)17 and diabetes 
(22%),18 together with a prevalence of coronary artery disease 
of 6%,19 once again higher in the urban setting. Urban loca-
tion, age, male gender, body mass index, hypertension, smok-
ing, dysglycemia, high serum cholesterol, and triglycerides 
were significant risk factors for coronary heart disease.
Other Gulf countries
Countries such as Saudi Arabia and the United Arab Em  irates 
have high populations of expatriate workers. Indeed, a recent 
study has shown that 80% of the United Arab Emirates 
workforce is of expatriate origin, and that the prevalence of 
cardiovascular risk factors among ethnic subgroups reflects 
the prevalence in the country of origin.20 The Gulf-RACE 
registry has analyzed the epidemiology of coronary heart 
disease in Bahrain, Kuwait, Oman, Qatar, Yemen, and 
the United Arab Emirates. A recent analysis of discharge 
diagnoses found that 39% had ST elevation myocardial 
infarction (STEMI)/left bundle branch block, 32% had non-
STEMI, and 29% had unstable angina.21 Interestingly, the 
proportion of patients receiving beta-blocker therapy during 
the first 24 hours of admission was lower in Gulf-RACE rela-
tive to GRACE (Global Registry of Acute Coronary Events), 
either for all patients with an acute coronary syndrome 
(65% versus 87%, respectively) or ST elevation myocardial 
infarction (62% versus 87%, respectively). Registry data 
from Kuwait demonstrated that the proportion of patients 
with acute myocardial infarction who received beta-blocker 
therapy was similar to that in the Gulf-RACE population, 
although the use of beta-blockers appeared to be decreasing 
(68% in 2004 and 63% in 2007).22
The proportion with either form of myocardial infarction 
was higher than that in the GRACE,23 while the proportion 
with unstable angina was lower. The mean age at presentation 
with myocardial infarction in Gulf-RACE was about 10 years 
lower than in GRACE (56 versus 66 years). In addition to 
smoking (see above), diabetes was more prevalent in Gulf 
residents than in GRACE (41% versus 26%), while lower 
prevalence values were observed for a diagnosis of hyperten-
sion (50% versus 65%) or hyperlipidemia (32% versus 50%). 
Broadly similar, if slightly lower, rates of previous angina 
pectoris, myocardial infarction, and percutaneous coronary 
intervention or coronary artery bypass grafting were observed 
in the Gulf-RACE versus GRACE population.
Tunisia, Algeria and Morocco
Like other countries in the region, Tunisia is undergoing an 
epidemiological transition,24 whereby overall life expectancy 
is increasing, but the risk of ischemic heart disease has 
also increased (Figure 3).25,26 This shift is accompanied by 
increasing urbanization; the proportion of Tunisian urban 
residents increased from 41% in 1966, to 60% in 1990, and 
to 66% in 2008.27
Recent data on cardiovascular risk factors in these   countries 
are unavailable, although in 1997, substantial pr  oportions of 
urban Tunisians were found to have hy  pertension (16%, defined 
as blood pressure .160/95 mmHg), d  iabetes (10%), or obesity 
(28%, defined as body mass index $30 kg/m2).28 A survey 
in Morocco in 2000 found prevalence values of 34% for 
hypertension, 7% for diabetes, and 29% for hypercholester-
olemia.29 The TAHINA (Epidemiological Transition And 
Health Impact In North Africa) project is currently investi-
gating the burden of noncommunicable disease in Tunisia 
and Algeria, and recent data d  emonstrate a high prevalence 
Table 1 Hypertension and adverse cardiovascular outcomes in 
the Egyptian National Hypertension Project10
Hypertension  
(n = 1559)
No hypertension  
(n = 754)
P
Coronary heart  
disease (%)
19.5 11.6 ,0.01
Heart failure (%) 13.3 5.8 ,0.0001
Renal failure (%) 5.3 1.9 0.0002
Left ventricular  
hypertrophy (%)
20 5 ,0.001
Note: Compiled from data presented by Sharraf et al.10
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
67
Coronary heart disease in the Middle EastTherapeutics and Clinical Risk Management 2012:8
of hypertension (30% and 24%, respectively) and obesity 
(27% and 21%, respectively).30 Thus, the demographic shift 
in North Africa is manifesting not only in increasing rates of 
cardiovascular mortality (particularly from ischemic heart 
disease), but also provides a reservoir of cardiovascular risk 
factors that will drive a sharp increase in the future burden 
of cardiovascular disease.
Other African countries
The high prevalence of human immunodeficiency virus in 
South Africa, with associated weight loss and early mortality, 
has distorted the epidemiological transition from commu-
nicable to noncommunicable diseases as a major source of 
morbidity and mortality.31 Heart failure currently appears to 
be the predominant presentation of cardiovascular disease in 
South Africa.32 However, a high prevalence of obesity (43%), 
hypertension (33%), and clustering of risk factors in a survey 
in the township of Soweto suggests that major problems with 
coronary heart disease will arise in South Africa in future.33
A recent systematic review has highlighted the need for 
well designed prospective cohort studies to quantify the bur-
den of cardiovascular disease in sub-Saharan Africa (defined 
as all of Africa south of the Sahara).34 Although 41 studies 
(from 11 countries in the region) were identified for evaluation, 
they were heterogeneous in their design, study populations, 
durations, and specified outcomes. These studies confirmed 
the presence of a health transition in sub-Saharan Africa, with 
cardiovascular risk factors such as hype  rtension, hypercholes-
terolemia, and smoking emerging as the most important ones 
for an emerging burden of cardiovascular disease. Abdominal 
obesity was found to explain the increased cardiovascular 
risk associated with urbanization of populations in Benin, 
consistent with these observations.35 The emergence of obesity 
as an increasingly important risk factor for hypertension in 
Sudanese children provides a worrying indication of future 
trends in developing nations in Africa.36
Implications for management  
of coronary heart disease  
in the region
Coronary prevention
There is a need for more recent data on the epidemiology 
of coronary heart disease in the region, given the projected 
sharp increases in the prevalence of coronary heart disease in 
the Middle Eastern countries described earlier. For example, 
the Egyptian National Hypertension Survey was carried out 
between 1991 and 1993. Collecting such data is challenging 
where infrastructure is lacking and populations are often tran-
sitory, although the national surveys and registries described 
above represent real progress.
Nevertheless, it is clear that the prevalence of cardiovas-
cular risk factors in North Africa and the Middle East is high. 
Thus, intervention to control hypertension and dyslipidemia, 
and to reduce the risk of developing diabetes is an urgent 
public health and clinical priority for these countries. Life-
style intervention (diet and exercise) is effective in reducing a 
number of cardiovascular risk factors simultaneously.37 Arab 
populations tend to ingest relatively large amounts of carbohy-
drates (eg, in the form of dates, figs, or refined sugars) and fats, 
which is consistent with the high prevalence of obesity.38–40 
Sedentary lifestyles are common in all urban populations, 
although higher levels of sedentary living have been reported 
for populations of Arab descent relative to other heritages.41,42 
Importantly, increased physical activity has been shown to 
reduce insulin resistance similarly in subjects of Arabian and 
European descent.43 Education of African/Middle Eastern 
populations on the benefits of an improved lifestyle will be 
vital in reducing the future burden of cardiovascular disease. 
However, achieving improved lifestyles in this population 
is challenging. For example, 82% of a randomly selected 
population attending a primary care clinic in Saudi Arabia 
were physically inactive, and cited a number of barriers to 
increased physical activity or improved diet.44 Cultural fac-
tors are important, and reaching older family members can be 
especially difficult where younger relatives are expected to 
run errands, allowing them to remain sedentary at home.
Re-examining the role of beta-blockade
Appropriate prescribing improves outcome for patients 
with coronary risk factors or with established coronary 
heart disease. Increased use of evidence-based treatments 
such as beta-blockers, angiotensin-converting enzyme inhibi-
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Figure 3 Demographic shift in North Africa: increased burden of ischemic heart 
disease (IHD) and decreasing burden of rheumatic heart disease (RHD) in hospitals 
in Tunisia.26
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
68
Almahmeed et alTherapeutics and Clinical Risk Management 2012:8
tors, aspirin, heparin, nitrates, and thrombolytics significantly 
reduced inhospital mortality rates following admission for 
acute myocardial infarction in Lebanon in 1996.45
An exhaustive review of the use of pharmacological 
treatments in patients with coronary heart disease is beyond 
the scope of this article. However, current guidelines in 
Europe recommend that beta-blockers have numerous 
applications in cardiovascular care, not only in the man-
agement of hypertension,4 but in patients with established 
coronary heart disease (Table 2).3,46 Nevertheless, the use 
of beta-blockers remains controversial in some groups of 
patients, and there is some evidence that the use of beta-
blockers varies within countries in the Middle East. For 
example, a large survey of the use of various cardiovascular 
therapies in patients with coronary heart disease in devel-
oping   countries revealed a lower use of beta-blockers.47 
In contrast, data from Lebanon, Saudi Arabia, Israel, and 
the United Arab Emirates from the REACH (Reduction of 
Atherothrombosis for Continued Health) registry showed 
that beta-blockers were prescribed for 61% of high-risk 
patients with atherothrombotic disease, which was higher 
compared with angiotensin-converting enzyme inhibitors 
(58%), diuretics (46%), calcium channel blockers (43%), or 
angiotensin II receptor blockers (21%).48
The proportions of patients who received a beta-blocker 
during hospitalization for acute myocardial infarction was 
35% in Lebanon, compared with higher proportions for the 
large, international GRACE registry (78%)49 or the Gulf-
RACE registry of Middle-Eastern countries (60% for Gulf-
RACE registry [2007], and 75% for the later Gulf RACE-2 
registry [2008–2009]).50–53 Within the first Gulf-RACE popu-
lation, men were more likely than women to receive a beta-
blocker at presentation (63% versus 56%, P = 0.006).50 The 
proportions receiving a beta-blocker at discharge were 77% 
for the Gulf-RACE registry54 and 80% for Gulf RACE-2.51 
Much of the controversy surrounding the use of beta-blockers 
has centered on their effects on glucose metabolism, with fear 
of exacerbation of dysglycemia, and the current evidence 
base suggests that this therapy should be avoided in patients 
with the metabolic syndrome.4 Meta-analyses have identified 
a significantly reduced risk of developing diabetes during 
treatment with an angiotensin-converting enzyme inhibitor 
Table 2 Summary of European guideline recommendations on the use of beta-blockers in patients with selected manifestations of 
established cardiovascular disease
Indication Recommended use of beta-blocker therapya Summary of potential benefit
Acute MI All patientsa,b Limitation of infarct size, ↓ life-threatening cardiac 
arrhythmias, relief of pain, reduced mortality  
(including sudden cardiac death)
Post-MI Long-term use in all survivors of MI 20%–25% improvement in survival through reductions 
in cardiac mortality, sudden cardiac death and 
reinfarction
NSTEMI-ACS Use acutely and long-term after the acute phase has passed Control myocardial ischemia and prevent acute 
myocardial infarction or reinfarction
Stable coronary  
artery disease
Long-term use for all patients Control ischemia, prevent infarction, improve survival
HF with reduced  
LV systolic function
Stable, mild-to-severe chronic heart failure (ischemic or non-
ischemic) and ↓LV ejection fraction, in NYHA class II–IV; use  
with ACEI for systolic dysfunction post-MI irrespective of 
presence/absence of HF symptoms
Long-term reduction in total and cardiovascular 
mortality, sudden cardiac death and death due to 
progression of HF
HF with preserved LV  
systolic function
No pharmacologic intervention has been shown to reduce 
morbidity and mortality in this population; managing cardiac 
ischemia and hypertension is considered of importance
Supraventricular  
arrhythmias
Atrial fibrillation, of atrial ectopic activity; use in selected 
individuals with sinus tachycardia (investigate primary cause)
Slow heart rate, improve control of ventricular rhythm
Ventricular arrhythmias Patients with ventricular arrhythmias related to sympathetic 
activation (eg, stress-induced arrhythmias, MI, perioperative,  
heart failure, catecholaminergic polymorphic ventricular 
tachycardia)
Improve control of ventricular rhythm, including 
reduced risk of sudden cardiac death
Cardiomyopathy Dilated cardiomyopathy (no specific recommendation for  
the use of beta-blockers in hypertrophic cardiomyopathy)
Beta-blockers reduce mortality similarly in HF of 
ischemic or nonischemic etiology
Notes: aWithout contraindications; bconsider intravenous use for ischemic pain resistant to opiates.3,42 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; HF, heart failure; LV, left ventricular; NYHA, New York Heart Association; 
MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction.
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versus placebo, while a slightly higher incidence of diabetes 
was observed with a beta-blocker relative to placebo.55 
However, it should be noted, that beta-blockers are equally 
effective in improving clinical outcomes in hypertensive 
diabetic or nondiabetic patients.56
A perception of greater effects on clinical outcomes of 
other cardiovascular therapies, relative to beta-blockers, 
has been based on the results of further meta-analysis 
and two outcomes trials (the Losartan Intervention For 
Endpoint Reduction study and the Anglo-Scandinavian 
Cardiac Outcomes Trial).57–59 These differences in efficacy 
may be accounted for by the considerable heterogeneity of 
trial designs (meta-analyses) or by differences in achieved 
blood pressure (outcomes trials). Other trials do not reveal 
a difference in efficacy between beta-blockers and other 
therapies, and an exhaustive meta-analysis involving 464,000 
patients enrolled in 147 randomized trials demonstrated no 
difference in the risk of coronary heart disease events in 
patients randomized to beta-blockers or to other therapies.60 
Age also did not influence the patient outcome of beta-
blocker therapy.52 There is no compelling evidence to suggest 
that beta-blockers are inferior to other therapies in terms of 
their potential for cardiovascular protection.
Concerns relating to adverse events with beta-blockers 
may also have been overstated. Briefing patients on the 
likelihood of sexual dysfunction increased the rate of 
reporting of this side effect, irrespective of its actual 
association with beta-blockade.61 The use of cardioselective 
beta-blockers may limit the potential for side effects, such 
as fatigue or sexual dysfunction.
Conclusion
The prevalence of coronary heart disease is high in 
countries in Africa and the Middle East. A high prevalence 
of cardiovascular risk factors implies a continuing burden 
of cardiovascular morbidity and mortality. Improving 
the lifestyles of patients in the region will be crucial for 
improving long-term outcomes, although cultural and 
other barriers will need to be overcome. Appropriate 
prescribing for the management of cardiovascular risk 
factors and established cardiovascular disease holds the 
key to improving outcomes in the short term. While more 
data on the appropriate use of all cardiovascular therapies 
in the Middle East would be welcome, data from Gulf-
RACE in particular suggest that beta-blocker therapy 
may be underused in some countries, relative to western 
populations, despite the proven benefits of this therapy in 
a broad range of patient subgroups.
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